Big Ideas 2023 | Molecular Diagnostics: Transforming Biological Signals Into Better Patient Outcomes

Download ARK's Big Ideas 2023 Report here: https://ark-invest.com/big-ideas-2023/ Next-generation sequencing (NGS) costs have collapsed, making molecular diagnostic tests more feasible and turbocharging our understanding of tumor biology. By leveraging artificial intelligence (AI), cancer diagnostics labs have created less invasive tests like liquid biopsies to supplement tissue biopsies. As proof of clinical utility accumulates, ARK estimates that the total addressable market (TAM) for molecular cancer diagnostic tests in the US is ~$95 billion, its revenue increasing more than 20% annually during the next five to ten years, from ~$5 billion in 2022 to $24 billion in 2030. Moreover, the collective enterprise value of molecular cancer testing companies should expand at a similar rate from ~$30 billion in 2022 to $145 billion in 2030. Listen in as Simon Barnett, ARK's Director of Research: Life Sciences, explains more. To enlighten investors on the long-term impact of innovation, we began publishing Big Ideas in 2017. This annual research report seeks to highlight the technological breakthroughs evolving today and creating the potential for super-exponential growth tomorrow. We believe that innovation is taking off now, corroborating our original research and boosting our confidence that ARK’s strategies are on the right side of change. We hope you enjoy Big Ideas 2023! To learn more about ARK: https://ark-invest.com For more updates, follow us on: Twitter: https://arkinv.st/Twitter LinkedIn: https://arkinv.st/LinkedIn Facebook: https://arkinv.st/Facebook Instagram: https://arkinv.st/Instagram Disclosure: http://arkinv.st/39rzF94